Catalyst
Slingshot members are tracking this event:
Teva Confirms PTAB’s Decisions on Two Patents in IPR Challenge to COPAXONE 40 mg
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| TEVA |
|
|
||||
Additional Information
On August 15, 2016, the PTAB declined a request for a post-grant review (PGR) on an additional COPAXONE® 40mg patent. Teva will defend four patents (‘250, ‘413, ‘302 and ‘776), all listed in the Orange Book with expiry dates into 2030, against a number of Abbreviated New Drug Application (ANDA) filers in U.S. District Court for the District of Delaware trial scheduled to begin in September 2016. The four patents remain valid and enforceable as does a fifth patent (‘874) recently issued and listed in the Orange Book.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 24, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Copaxone, Patents, Glatiramer Acetate Injection, Intellectual Property, Reduction Of Relapses, Relapsing-remitting Multiple Sclerosis
